Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 apalutamide plus GnRH agonist with primary radiation therapy for high-risk localized or locally advanced prostate cancer
NL-OMON53090Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Apalutamide arm with Placebo control arm (2 arms). Primary endpoint: Metastasis-free survival. Started Jul 2017; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON53090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53090.